Dr Sivakumar Thurairajasingam

Associate Professor (Practice)

Jeffrey Cheah School of Medicine & Health Sciences

Email: sivakumar.thurairajasingam@monash.edu
Tel: +607 219 0600  ext: 619
Office: Clinical School, JB

Profile Summary

Associate Professor Sivakumar A/L Thurairajasingam is Associate Professor (Practice) in Psychiatry and Deputy Head (Education) of the Clinical School Johor Bahru.

Dr Sivakumar joined Monash University Malaysia on 1st August 2006 as a lecturer. He obtained his MBBS from the University of Mangalore, India (1994) and then went on to complete his Master in Medicine in Psychiatry in 2002, at the Universiti Sains Malaysia. He has served in the medical field for the past 10 years at the Kota Bharu General Hospital, Universiti Sains Malaysia Hospital in Kubang Kerian, and Hospital Permai. He previously served as Head of the Substance Abuse Unit, Hospital Permai, Coordinator of the Psychiatry Research Unit at Hospital Permai and also as the State Coordinator of the National Methadone Maintenance Programme. His special interests are in the field of psychiatry research as well as drug and alcohol treatment/research. He is involved with Year 3 and Year 4 teaching of the Medical Programme at the Johor Bahru campus.

Qualifications

  • Medical Bachelor, Bachelor of Surgery (MBBS), University of Manglore, Karnataka, India (1994)
  • Master of Medicine (MMed Psych) University Sains Malaysia  (2002)
  • Certificate in Clinical Hypnosis, London College of Clinical Hypnosis (2007)

Present Appointments

Clinical Appointments

  • Consultant Psychiatrist & Associate Professor, School of Medicine & Health Sciences, Monash University, Malaysia (since 2015)
  • Consultant Psychiatrist & Senior Lecturer, School of Medicine & Health Sciences, Monash University, Malaysia (2006 - 2015)
  • Honorary Consultant Psychiatrist, Mood Disorders Clinic, Hospital Sultanah Aminah, Johor Bahru (since 2008)
  • Honorary Consultant Psychiatrist, Addiction Liaison Services, Hospital Sultanah Aminah, Johor Bahru (since 2008)
  • Consultant, Methadone Substitution Clinic, National Anti-Narcotics Agency, Johor Bahru, Malaysia.
  • Consultant Psychiatrist, Columbia Asia Hospital Johor Bahru, Johor.
  • Certified Trainer, Asian Centre for Certification & Education of Addiction Professionals (ACCE), Universal Treatment Curriculum (UTC) for Substance Use Disorder, Colombo Plan
  • Certified National Trainer for the National Medication Assisted Treatment  (MAT) Program for Opioid Dependence

Administrative Appointments

  • Deputy Head (Education), Clinical School Johor Bahru, School of Medicine & Health Sciences, Monash University, Malaysia (since 2017)
  • Year 4 Coordinator, MBBS Program, Monash University Malaysia
  • Psychological Medicine Coordinator, MBBS Program, Monash University
  • Committee member, MBBS-Assessment Sub-Committeee, Monash University
  • Committee member, Malaysia Program Curriculum Committee, Monash University

Service Related Appointments

  • Consultant, Drug Advisory Program, Colombo Plan
  • Consultant, Intervention Group for Alcohol Misuse (IGAM), Sabah
  • Advisor, Befriender’s Johor Bahru
  • Life Zone – President (NGO organisation on Addiction / HIV)

Member of Professional Organizations

  • Secretary, Addiction Medicine Association of Malaysia (AMAM)
  • Malaysian Psychiatric Association - Member
  • Johor Mental Health Association – Vice-president
  • Malaysian Medical Association – Member

Working Experience

  • 1993–1994 House Officer, Kasturba Hospital Manipal, Karnataka, India  & CSI Hospital, Erode, Tamil Nadu, India (General Medicine, General Surgery, Orthopaedics, Paediatrics, Neonatalogy, Obstetrics & Gynaecology, Community Medicine)
  • 1995–1996 House Officer Hospital Kota Bharu, Kelantan (Obstetrics & Gynaecology, General Medicine, General Surgery)
  • 1996–1997 Medical Officer Hospital Kota Bharu, Kelantan(Orthopaedics, Psychiatry)
  • 1997–2002 Psychiatric Trainee (Residency) (Hospital Kota Bharu, Hospital Universiti Sains Malaysia, Hospital Bahagia)
  • 2002–2003 Clinical Psychiatrist, Hospital Permai Johor Bahru
  • 2003–2006 Psychiatrist, Hospital Permai Johor Bahru
  • 2006 till currently Consultant Psychiatrist, Monash University Malaysia

Specific Addiction Training

  • Training on Addiction Severity Index, Substance Abuse Research Center & Yale University, 2003.
  • Training Workshop on Methadone Maintenance Therapy, Ministry of Health Malaysia, 2005.
  • Training Workshop on Drug Substitution Therapy (DST Protocol), Ministry of Health Malaysia, 2005.
  • Training Workshop in Theory & Practice of Motivational Interviewing, Netherlands Centre for Motivation & Change, 2005.
  • Training Workshop on Behavioural Drug & Risk Counseling (BDRC) for Opioid Dependent Individuals, Substance Abuse Research Center & Yale University, 2007
  • Substitution Therapy Counselling Workshop, Ministry of Health Malaysia, 2010.
  • Workshop in Acceptance & Commitment Therapy (ACT), Melbourne 2012
  • Basic Counselling Course for Gambling Addiction Therapists, Singapore 2012.
  • Denial Management Counselling. CENAPS Asia, Chiang Mai, Thailand 2012.

GCP Training

  • GCP training by Johnson & Johnson Pharmaceutical Research & Development (2004)
  • GCP training by Clinical Research Centre, Ministry of Health Malaysia (2004)

Research & Education

Area of Expertise & Interest

Addiction Psychiatry

  • Establishing, setting up and managing the Substance Abuse Clinic and Drug Substitution Therapy Clinic (Methadone / Buprenorphine) at Hospital Permai Johor Bahru (2003-2006)
  • Establishing, setting up and managing the Johor Bahru Anti-Narcotic Agency Methadone Substitution Clinic (from 2007 onwards)
  • Establishing and managing the Addiction Liason Unit at Hospital Sultanah Aminah Johor Bahru (from 2010 onwards)
  • National trainer for the National Drug Substitution Therapy (NDST) Program (since 2007)

Mood Disorders

  • Establishing, setting up and managing the Mood Disorders Clinic at Hospital Sultanah Aminah Johor Bahru (2008 onwards)

Harm Reduction

Investigator Initiated Research

Cannabis and Schizophrenia: a comparison of drug-abusing and non drug-abusing patients on clinical correlates and schizophrenic psychopathology (Principal Investigator)

Future of the Long Stay patients: demographic characteristics and the need for support/housing (Principal Investigator)

Exploring the Needle Use Culture; a comparison between needle users and non-users from a cultural, social, and mental health perspective (Principal Investigator)

Co-morbidity of Depression among Opioid Abusers: A Comparison between Needle Users and Non-Needle Users (Principal Investigator)

Depression among Type II Diabetic Patients (Co-Investigator)

Outcome of Methadone Maintenance Therapy versus Buprenorphine-Naloxone combination therapy among opiate dependence patients receiving Highly Active Antiretroviral   Treatment in University Malaya Medical Center and Hospital Sungai Buloh: Twelve months, open labelled, randomised controlled trial. Research ID: 15212 (Co-Investigator)

Industry Related Research Funding And Clinical Trials

Sertindole versus Risperidone Safety Outcome Study: A Randomised, Partially Blind, Parallel-Group, Active-Controlled, Post Marketing Study (SCoP 99824) - Co–Investigator (Sponsor/Grant from Lundbeck)

Evaluation of Efficacy and Safety of Long Acting Risperidone Microspheres in Patients With Schizophrenia or Other Psychotic Disorders When Switching From Typical Depot or Oral Neuroleptics to Long Acting Risperidone Microspheres. – Co-Investigator (Sponsor/Grant from Jansssen-Cilag)

A 6-week , international, multicenter, double-blind, ramdomized parallel-group, phase III study to evaluate the switching from immediate release Quetiapine Fumarate to sustained release Quetiapine Fumurate (SEROQUEL) in patients with schizophrenia (Sponsor/Grant from Astra Zeneca)

A randomized, double-blind, placebo and active controlled, parallel group, dose response study to evaluate the efficacy and safety of 3 fixed dosages of extended release OROS® Paliperidone (3, 9 and 15mg/day) and Olanzapine (10mg/day) in the treatment of subjects with schizophrenia (R076477-SCH-305). – Co-Investigator (Sponsor/Grant from Johnson & Johnson Pharmaceutical Research and Development)

An open label extension to R076477-SCH-305 to evaluate the efficacy and safety of 3 fixed dosages of extended release OROS® Paliperidone (3, 9 and 15mg/day) in the treatment of subjects with schizophrenia (R076477-SCH-305). – Co-Investigator (Sponsor/Grant from Johnson & Johnson Pharmaceutical Research and Development)

Open extension study evaluating the safety and tolerability of oral Ziprasidone in the treatment of schizophrenic patients (A1281072). – Co-Investigator (Sponsor/Grant from Pfizer)

A prospective, randomized, multi-center, double-blind, flexible dose, parallel group study to determine the antipsychotic effect of iloperidone (dose range of 4-16mg/day) as compared with haloperidol (dose range 5-20mg/day) and to determine the safety of iloperidone in schizophrenic patients (ILP3002). - Co-Investigator (Sponsor/Grant from Novartis)

A Randomized, Double-Blind, Placebo-Controlled Study to explore the efficacy and safety of Risperdal Long-Acting Intramuscular Injectable in the prevention of mood episodes in Bipolar I Disorder, with open-label extension. – Co-Investigator (Sponsor/Grant from Johnson & Johnson Pharmaceutical Research and Development)

Industry Research, Principal Investigator Research Title: A Multicenter, Randomized, Double-blind study to evaluate the Efficacy, Safety & Tolerability of an oral Aripiprazole/Escitalopram combination therapy in patients with Major Depressive Disorder NMRR ID: NMRR-10-899-6790 – Principal Investigator (2011) (Sponsor/Grant from Otsuka Pharma Development & Commercialization, Inc)

An open, national, multicentric study over 6 weeks of treatment, with the objective of evaluating the efficacy and safety of Valdoxan in the treatment of major depressive disorder in an out patient setting (Protocol No: DM4- 68784094) – Principal Investigator (2012) (Sponsor/Grant from Novotech (Australia) Pty Limited)

Randomized, double-blind, placebo-controlled, multi-center trial to assess the safety and efficacy of RP5063 in subjects with an acute exacerbation of schizophrenia or schizoaffective disorder (REFRESH). Protocol No: RVP-20-001 – Principal Investigator (2012) (Sponsor Sristek Clinical Research Solutions Ltd.

Efficacy and safety of agomelatine (25 mg/day) with blinded potential adjustment to 50 mg/day) for 12 weeks in non-depressed outpatients with Generalized Anxiety Disorder. A 12-week randomized, double blind, versus venlafaxine XR (75 mg/day) with blinded potential adjustment up to 225 mg/day), 2-arm parallel groups, international multicentre study. Protocol No: CL3-20098-078 – Principal Investigator (2013) (Sponsor Institut de Recherches Internationales Servier [I.R.I.S.])

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Month Trial of Leuco-methylthioninum bis(hydromethanesulfonate) in Subjects with Mild to Moderate Alzheimer's Disease. Protocol No: TRx-237-015 – Co-Investigator (2013) (Sponsor TauRx Therapeutics Ltd).

Efficacy and safety of Tianeptine oral administration (25 to 50 mg/day) in elderly patients suffering from Major Depressive Disorder. A 8-week, randomized, double-blind, flexible-dose, parallel groups, placebo-controlled, international, multicentre study with escitalopram as active control, followed by an optional double-blind extension treatment period of 16 weeks. Protocol No: CL3-01574-237 - Principal Investigator (2014) (Institut de Recherches Internationales Servier)

Publications

Mohamed MN, Marican S, Othman MH, Thurairajasingam S, Ali N (2017) Validation of Addiction Severity Index (5th Edition) Bahasa Melayu Version (ASI-5-BM). MOJ Addict Med Ther 4(2): 00075. DOI: 10.15406/mojamt.2017.04.00075

George P, Balasingam V, Thurairajasingam S, Ramasamy P, Mohd Yusof H, Mohd Yasin MA, Shah Z. Methadone complications amongst opioid-dependent patients in Malaysia: A case series. Drug and Alcohol Review (2016) DOI: 10.1111/dar.12456

George P, Ramasamy P, Thurairajasingam S, Shah Z. Patients that Benefit from Buprenorphine-Naloxone on Medically Assisted Treatment for Opioid Dependence in Malaysia: A Case Series. Malaysian Medical Journal. Vol.70, No 4, Aug 2015

Thurairajasingam S. (2014). Psychological Treatments for Substance Use. In Handbook on the Management of Substance Abuse in Malaysia (eds. George P, Ramasamy P, Thurairajasingam S, Benedict I), pp. 93-108, Addiction Medicine Association of Malaysia, 2014.

Thurairajasingam S. (2014). Special Populations: Substance Use in Pregnancy & Childbirth. In Handbook on the Management of Substance Abuse in Malaysia (eds. George P, Ramasamy P, Thurairajasingam S, Benedict I), pp. 79-87, Addiction Medicine Association of Malaysia, 2014.

Thurairajasingam S. (2014). Cannabis. In Handbook on the Management of Substance Abuse in Malaysia (eds. George P, Ramasamy P, Thurairajasingam S, Benedict I), pp. 37-46, Addiction Medicine Association of Malaysia, 2014.

Thurairajasingam S. (2014). MDMA and Hallucinogens. In Handbook on the Management of Substance Abuse in Malaysia (eds. George P, Ramasamy P, Thurairajasingam S, Benedict I), pp. 31-36, Addiction Medicine Association of Malaysia, 2014.

Thurairajasingam S. (2014). Why do People Use Substances? In Handbook on the Management of Substance Abuse in Malaysia (eds. George P, Ramasamy P, Thurairajasingam S, Benedict I), pp. 7-14, Addiction Medicine Association of Malaysia, 2014.

National Clinical Guidelines and Procedures for the use of Buprenorphine-Naloxone in the Treatment of Opioid Dependence, second edition January 2014.

Malaysian Consensus Statement for the Treatment of Bipolar Disorder. CMP Medica 2007

Malaysian Guidelines on the use of Buprenorphine-Naloxone combination for Opioid Dependence 2007.

Malaysian Consensus Statement for Long Acting Injectable Atypical Antipsychotic (LAIAA) 2006.

Proceedings of Conferences

International

2015

  • Training of Trainers for National Bahama Trainers on the Universal Treatment Curricula “Co-Occurring Disorders”. Nassau Jun 2015.
  • The Pharmacology of Opioid Safety: Drug Interactions of Clinical Importance with Methadone and Buprenorphine/Naloxone Use. Pre Conference Workshop 1st International Conference of Addiction, Prevention and Treatment (ICAPT). KL 2015
  • Buprenorphine-Naloxone, a Better Choice for Opioid Dependence? 1st International Conference of Addiction, Prevention and Treatment (ICAPT). KL 2015

2014

  • Colombo Plan Training on Co-Occurring Disorders, 3rd – 6th Mar, Dubai

2013

  • Workforce Development in Asia: From a Harm Reduction Perspective.2nd APBAM, Singapore. 23rd May
  • Colombo Plan Training on Co-Occurring Disorders, 11th-13th Nov, KL

2012

  • “Workshop on Co-occurring Disorders”. Facilitator, Drug Advisory Programme (DAP) of the Colombo Plan Secretariat, Melaka, Malaysia.

2011

  • “Better Remission-Better Functionality, The Importance of Initiating Treatment Addressing Depressed Patients Needs”, Speaker at Lilly 8th SEA Neuroscience Meeting, Bangkok, Thailand.
  • “Co-morbidity of Depression among Opioid Abusers: A Comparison between Needle Users and Non-Needle Users”, Poster presentation at Global Addiction Conference, Lisbon, Portugal.
  • Speaker, 2nd International Conference on Addiction Medicine (2nd ICAM), Kuching, Sarawak.

2010

  • Speaker at the 1st Asia Pacific Behavioural & Addiction Medicine Conference, Singapore.
  • Speaker at the 7th Lilly South East Asia Neuroscience Conference, Kuala Lumpur
  • “A Comparison between Needle Users and Non-Users from a Cultural, Social, Environmental and Mental Health Perspective”. Poster presentation at the 9th Europad Conference, Zagreb, Croatia.

2009

  • Speaker at the 5th Lilly SEA CNS Conference, Manila, Philippines.

2008

  • Speaker at 4th Lilly Southeast Asia Neuroscience Conference, Singapore.

2007

  • “Exploring the Needle Use Culture; a comparison between needle users and non-users from a cultural, social, and mental health perspective”. Free paper at APSAD, Auckland, New Zealand.
  • Speaker at 1st International Conference on Addiction Medicine, Kuala Lumpur, Malaysia.

2004

  • “Cannabis and Schizophrenia: a comparison of drug-abusing and non drug-abusing patients on clinical correlates and schizophrenic psychopathology”. Poster presentation at 1st Asia Pacific Institute of Addictions, Singapore.

National

2015

  • Of Facts and Fables: Exploring Methamphetamine Addiction. Johor Mental Health Convention April 2015
  • GP Workshop on Depression. KL April 2015
  • Training of Trainers for National AADK Trainers on the Universal Treatment Curricula “Co-Occurring Disorders”. Sg. Petani May 2015.
  • GP Workshop on Depression. Kuching Jul 2015
  • Concept of Addiction. “One Stop Centre for Addiction” Workshop. JB Jul 2015
  • New Psychoactive Substances. “One Stop Centre for Addiction” Workshop. JB Jul 2015
  • Addiction as a Chronic Disease. Mesyuarat Jawatankuasa Rawatan & Pemulihan AADK. KL Aug 2015
  • Managing Opioid Dependent Patients with Co morbidities in Malaysia. CME Hospital Kota Bharu Aug 2015
  • Managing Opioid Dependent Patients with Co morbidities in Malaysia. CME Hospital Ipoh Aug 2015
  • Managing Opioid Dependent Patients with Co morbidities in Malaysia. CME Hospital Selayang Sept 2015

2014

  • Sabah Mental Health Convention 26th-27th Mar, Kota Kinabalu
  • Johor Mental Health Convention 25th-26th Apr, Johor Bahru
  • National Conference in Addiction Medicine (NatCAM) 16th-18th May, KL
  • Intervention Group for Alcohol Misuse (IGAM) workshop 10th May, Kota Kinabalu.

2013

  • Co-morbid Depression in Substance Abusers, Standalone Psychiatry Meet. April 13th & 14th
  • Unipolar vs. Bipolar Depression: Complications of Treatment, Hospital Permai JB. 26th April
  • Health Inequity, AMSA Post Conference Seminar, KL. 11th May
  • PTSD, AMSA Post Conference Seminar, KL. 11th May
  • Motivational Interviewing Workshop for Occupational Therapists, Hospital Permai JB. 21st May
  • Johor Mental Health Convention, 13-15th Jun
  • AZ Neuroscience National Summit, 5th-6th July
  • Ipoh Mental Heath Convention, 29th Aug
  • Anger Management Workshop, Hospital Permai, 24th Oct
  • Grief Workshop for Breast Ca Supporters, 26th Oct

2012

  • Facilitator for “Alcohol Abuse Intervention Workshop”, Johor Bahru.
  • “Evidence Based Antidepressant: Efficacy of Agomelatine”. Speaker at Valdoxan Master Class II, Penang.
  • “Unmet needs in treatment of anxious depressed patients”. Speaker at the MSD Psychiatry Standalone Meeting, Penang.
  • “How do I access progress and manage common threats to positive treatment outcomes?” Speaker at Jiwa Baru Expert Meeting, Port Dickson.
  • “The Role of DST on the Psychopathological Symptoms of Heroin Addicts”. Speaker at the 14th Johor Mental Health Convention 2012, Johor Bahru.
  • Facilitator for “Motivational Enhancement Therapy (MET) Workshop” at the 14th Johor Mental Health Convention 2012, Johor Bahru
  • Facilitator at the IGAM Training Workshop, Kota Kinabalu.
  • “Pharmacotherapy for treatment-resistant schizophrenia: What do we do with the persistently resistant people?” Speaker at Hospital Permai CME, Johor Bahru.
  • Facilitator at the Counselling Workshop for NGOs, Johor Bahru.
  • Facilitator at “Evidence-based Medicine in Bipolar Disorder Workshop”, Kuala Lumpur.

2011

  • “De-stressing Medical Students Distress”. Speaker at the International Medical Students Conference, Melaka.
  • Speaker at “13th Johor Mental Health Convention, Johor Bahru.

2010

  • Speaker at the Lilly Bipolar Conference, Kuala Lumpur.
  • Facilitator at the Alcohol Abuse Intervention workshop, Kota Kinabalu, Sabah.
  • “Nicotine Addiction”. Speaker at the Smoke free Environment Workshop, Penang.
  • Speaker at the Pfizer Neuroscience Conference, Port Dickson.
  • Speaker at the 12th Johor Mental Health Convention, Johor Bahru.
  • Speaker at the Jiwa Baru Workshop, Kuala Lumpur.
  • “Why do Mental Illness & Drug Addiction Co-exist?”. Speaker at the 7th KL Mental Health Convention, Kuala Lumpur.
  • Speaker at the 8th Perak Mental Health Convention, Ipoh, Perak.
  • Speaker at “Kursus Kelantan Psychiatry CME Peringkat Negeri Kelantan, Kota Bharu, Kelantan.

2009

  • “Brief Intervention for Substance Dependence Workshop”. Facilitator, Kota Kinabalu, Sabah.
  • Speaker at the 6th National Conference on Addiction Medicine, Kuala Lumpur.

2008

  • “Current Issues in Community based DST”. Speaker at 5th National Conference on Addiction Medicine, Kuantan, Pahang.
  • “Advances in Psychiatric Therapeutics”. Speaker at 10th Johor Mental Health Convention, Johor Bahru, Johor.
  • Speaker at Jiwa Baru Expert Meeting, Kuching, Sarawak.
  • Speaker at 1st National Mood & Sleep Disorders Conference, Kuala Lumpur.
  • “Treatment Resistant Schizophrenia”. Speaker at Workshop on Psychosocial Management of Treatment Resistance Schizophrenia, Johor Bahru.

2007

  • “Workshop on Bipolar Mood Disorder”. Facilitator, Johor Bahru.
  • “Towards Fostering Better Patient Care Workshop”. Speaker, Perak.

2006

  • “Prevention & Early Treatment of Drug Addiction – Strategy & Challenges Ahead. Speaker at the 3rd National Conference on Addiction Medicine, Kuala Lumpur.
  • Speaker at the 3rd Johor Psychiatric Updates – “Anxiety & Depressive Disorders”, Johor Bahru.
  • Speaker at the “Seminar Kesihatan Minda Kastam Johor”, Johor Bahru.

2005

  • Speaker at “Seminar Kaunselor Masa Kini Mendepani Arus Penagihan Semasa yang Kian Kompleks”. Kota Tinggi, Johor.
  • Speaker at Program Seminar “Psychotherapeutics for Survivors of Trauma”. Johor Bahru.
  • Speaker at “Seminar Meningkatkan Kompetensi Pegawai Pemulihan ke Arah Membantu Klien Menjana Gaya Hidup Sihat”. Johor Bahru.
  • Speaker at “Kursus HIV / AIDS: Updates & Kaunseling. Mersing, Johor.
  • Speaker at “Kempen Task Force Tempat Kerja Bebas Dadah”. Johor Bahru.
  • Speaker at 2nd National Conference on Addiction Medicine, Kuala Lumpur.

2004

  • Speaker at “Kursus ke Arah Kecermerlangan Era Usia Emas”. Johor Bahru.
  • Speaker at the Johor Occupational Therapists Conference, Johor Bahru.
  • Speaker at “2nd Johor Psychiatric Updates on Anxiety & Depressive Disorders. Johor Bahru.
  • Speaker at “Kursus Klinik Berhenti Merokok”. Johor Bahru.

2003

  • Speaker at “Kursus Kaunseling HIV / AIDS”. Johor Bahru.
  • Speaker at “Sesi Perbincangan: Sempena Sambutan Hari Kesihatan Mental Sedunia Peringkat Negeri Johor”. Johor Bahru.
  • “Clinical, Social, Psychological Implications of Drug Addiction”. Speaker at Persidangan Drug of Abuse Testing – Laoratory Perspective, Johor Bahru.

2002

  • Cannabis and Schizophrenia: a comparison of drug-abusing and non drug-abusing patients on clinical correlates and schizophrenic psychopathology. Free paper at 9th Malaysian Conference On Psychological Medicine, Kuala Lumpur.
  • “Future of the Long Stay patients : demographic characteristics and the need for support/housing”. Free paper at 4th Johor Mental Health Convention, Johor Bahru.

2001

  • Cannabis and Schizophrenia: a comparison of drug-abusing and non drug-abusing patients on demographic characteristics. Free paper at Lilly Postgraduate Conference, Kuala Lumpur.

Research Grants

An open, national, multicentre study over 6 weeks of treatment, with the objective of evaluating the efficacy and safety of Valdoxan in the treatment of major depressive disorder in an outpatient setting — VERY (2012)
NMRR ID: DM4-68784094
Grant: RM10,000

REFRESH: Randomized, double-blind, placebo-controlled, multi-center trial to assess the efficacy and safety RP5063 in subjects with an acute exacerbation of schizophrenia or schizoaffective disorder
NMRR ID: RVP-20-001
Grant: USD35,000 (2012)

Efficacy and safety of agomelatine (25 mg/day with blinded potential adjustment to 50 mg/day) for 12 weeks in non-depressed outpatients with Generalized Anxiety Disorder. A 12-week randomized, double blind, versus venlafaxine XR (75 mg/day with blinded potential adjustment up to 225 mg/day), 2-arm parallel groups, international multicenter study.
NMRR ID: 12762
Grant: RM95,000 (2012)

Efficacy and safety of Tianeptine oral administration (25 to 50 mg/day) in elderly patients suffering from Major Depressive Disorder.
A 8-week, randomized, double-blind, flexible-dose, parallel groups, placebo-controlled, international, multicentre study with escitalopram as active control, followed by an optional double-blind extension treatment period of 16 weeks.
Grant: RM166,995 (2013)

No content

Prizes and Distinctions

  • 1st Place, Best Postgraduate Research Paper, Lilly Postgraduate Conference, Kuala Lumpur 2001.
  • 1st Place, Best Paper Presentation, 9th Malaysian Conference of Psychological Medicine (MCPM), Kuala Lumpur 2002
  • 2nd Place, Best Poster Presentation, 1st Asia Pacific Institute of Addictions, Singapore 2004
  • PVC Award for Excellence in Teaching & Education, 2008
  • Excellent Service Award, National Anti Drug Agency, 2011
  • Iskandar Malaysia Social Hero Awards (IMSHA) for Human Empowerment, 2014